Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mephedrone (4-Methylmethcathinone): Acute Behavioral Effects, Hyperthermic, and Pharmacokinetic Profile in Rats

K. Šíchová, N. Pinterová, M. Židková, RR. Horsley, E. Lhotková, K. Štefková, Č. Vejmola, L. Uttl, M. Balíková, M. Kuchař, T. Páleníček,

. 2018 ; 8 (-) : 306. [pub] 2017

Language English Country Switzerland

Document type Journal Article

Mephedrone (MEPH) is a synthetic cathinone derivative with effects that mimic MDMA and/or cocaine. Our study in male Wistar rats provides detailed investigations of MEPH's and its primary metabolite nor-mephedrone's (nor-MEPH) pharmacokinetics and bio-distribution to four different substrates (serum, brain, lungs, and liver), as well as comparative analysis of their effects on locomotion [open field test (OFT)] and sensorimotor gating [prepulse inhibition of acoustic startle reaction (PPI ASR)]. Furthermore, in order to mimic the crowded condition where MEPH is typically taken (e.g., clubs), the acute effect of MEPH on thermoregulation in singly- and group-housed rats was evaluated. Pharmacokinetics of MEPH and nor-MEPH after MEPH (5 mg/kg, sc.) were analyzed over 8 h using liquid chromatography with mass spectrometry. MEPH (2.5, 5, or 20 mg/kg, sc.) and nor-MEPH (5 mg/kg, sc.) were administered 5 or 40 min before the behavioral testing in the OFT and PPI ASR; locomotion and its spatial distribution, ASR, habituation and PPI itself were quantified. The effect of MEPH on rectal temperature was measured after 5 and 20 mg/kg, sc. Both MEPH and nor-MEPH were detected in all substrates, with the highest levels detected in lungs. Mean brain: serum ratios were 1:1.19 (MEPH) and 1:1.91 (nor-MEPH), maximum concentrations were observed at 30 min; at 2 and 4 h after administration, nor-MEPH concentrations were higher compared to the parent drug. While neither of the drugs disrupted PPI, both increased locomotion and affected its spatial distribution. The effects of MEPH were dose dependent, rapid, and short-lasting, and the intensity of locomotor stimulant effects was comparable between MEPH and nor-MEPH. Despite the disappearance of behavioral effects within 40 min after administration, MEPH induced rectal temperature elevations that persisted for 3 h even in singly housed rats. To conclude, we observed a robust, short-lasting, and most likely synergistic stimulatory effect of both drugs which corresponded to brain pharmacokinetics. The dissociation between the duration of behavioral and hyperthermic effects is indicative of the possible contribution of nor-MEPH or other biologically active metabolites. This temporal dissociation may be related to the risk of prolonged somatic toxicity when stimulatory effects are no longer present.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010054
003      
CZ-PrNML
005      
20210316130125.0
007      
ta
008      
180404s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fpsyt.2017.00306 $2 doi
035    __
$a (PubMed)29375408
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Šíchová, Klára $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.
245    10
$a Mephedrone (4-Methylmethcathinone): Acute Behavioral Effects, Hyperthermic, and Pharmacokinetic Profile in Rats / $c K. Šíchová, N. Pinterová, M. Židková, RR. Horsley, E. Lhotková, K. Štefková, Č. Vejmola, L. Uttl, M. Balíková, M. Kuchař, T. Páleníček,
520    9_
$a Mephedrone (MEPH) is a synthetic cathinone derivative with effects that mimic MDMA and/or cocaine. Our study in male Wistar rats provides detailed investigations of MEPH's and its primary metabolite nor-mephedrone's (nor-MEPH) pharmacokinetics and bio-distribution to four different substrates (serum, brain, lungs, and liver), as well as comparative analysis of their effects on locomotion [open field test (OFT)] and sensorimotor gating [prepulse inhibition of acoustic startle reaction (PPI ASR)]. Furthermore, in order to mimic the crowded condition where MEPH is typically taken (e.g., clubs), the acute effect of MEPH on thermoregulation in singly- and group-housed rats was evaluated. Pharmacokinetics of MEPH and nor-MEPH after MEPH (5 mg/kg, sc.) were analyzed over 8 h using liquid chromatography with mass spectrometry. MEPH (2.5, 5, or 20 mg/kg, sc.) and nor-MEPH (5 mg/kg, sc.) were administered 5 or 40 min before the behavioral testing in the OFT and PPI ASR; locomotion and its spatial distribution, ASR, habituation and PPI itself were quantified. The effect of MEPH on rectal temperature was measured after 5 and 20 mg/kg, sc. Both MEPH and nor-MEPH were detected in all substrates, with the highest levels detected in lungs. Mean brain: serum ratios were 1:1.19 (MEPH) and 1:1.91 (nor-MEPH), maximum concentrations were observed at 30 min; at 2 and 4 h after administration, nor-MEPH concentrations were higher compared to the parent drug. While neither of the drugs disrupted PPI, both increased locomotion and affected its spatial distribution. The effects of MEPH were dose dependent, rapid, and short-lasting, and the intensity of locomotor stimulant effects was comparable between MEPH and nor-MEPH. Despite the disappearance of behavioral effects within 40 min after administration, MEPH induced rectal temperature elevations that persisted for 3 h even in singly housed rats. To conclude, we observed a robust, short-lasting, and most likely synergistic stimulatory effect of both drugs which corresponded to brain pharmacokinetics. The dissociation between the duration of behavioral and hyperthermic effects is indicative of the possible contribution of nor-MEPH or other biologically active metabolites. This temporal dissociation may be related to the risk of prolonged somatic toxicity when stimulatory effects are no longer present.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pinterová, Nikola $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic. Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Židková, Monika $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Horsley, Rachel R $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.
700    1_
$a Lhotková, Eva $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.
700    1_
$a Štefková, Kristýna $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.
700    1_
$a Vejmola, Čestmír $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic. Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Uttl, Libor $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic. Department of Physiology, Faculty of Science, Charles University, Prague, Czech Republic.
700    1_
$a Balíková, Marie $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Kuchař, Martin $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic. Forensic Laboratory of Biologically Active Compounds, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic.
700    1_
$a Páleníček, Tomáš $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic. Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
773    0_
$w MED00174602 $t Frontiers in psychiatry $x 1664-0640 $g Roč. 8, č. - (2018), s. 306
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29375408 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20210316130121 $b ABA008
999    __
$a ind $b bmc $g 1287539 $s 1006866
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 8 $c - $d 306 $e 2017 $i 1664-0640 $m Frontiers in psychiatry $n Front Psychiatry $x MED00174602
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...